Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.

Ann Oncol. 2019 Sep 1;30(9):1417-1427. doi: 10.1093/annonc/mdz204.

PMID:
31268127
2.

[Biomarker, what is the pathologist's role?]

Bibeau F.

Ann Pathol. 2019 Jun;39(3):177-178. doi: 10.1016/j.annpat.2019.05.002. French. No abstract available.

PMID:
31160017
3.

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A.

Ann Oncol. 2019 May 6. pii: mdz116. doi: 10.1093/annonc/mdz116. [Epub ahead of print]

PMID:
31056702
4.

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P.

J Thorac Oncol. 2019 Jul;14(7):1204-1212. doi: 10.1016/j.jtho.2019.03.024. Epub 2019 Apr 15.

PMID:
30999109
5.

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D; EORTC 10994/BIG 1-00 study investigators.

Br J Cancer. 2019 Apr;120(9):913-921. doi: 10.1038/s41416-019-0420-y. Epub 2019 Mar 22.

PMID:
30899086
6.

[Augmented pathology, future or present ?]

Badoual C, Bibeau F.

Ann Pathol. 2019 Apr;39(2):71-72. doi: 10.1016/j.annpat.2019.02.009. Epub 2019 Mar 14. French. No abstract available.

PMID:
30879695
7.

[Tumor banks and complex data management: Current and future challenges].

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B.

Ann Pathol. 2019 Apr;39(2):137-143. doi: 10.1016/j.annpat.2019.01.017. Epub 2019 Feb 25. French.

PMID:
30819623
8.

National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016.

Boutanos C, Capdepont M, Svrcek M, Thélu F, Guedj N, Poizat F, Bibeau F, Turlin B, Rousseau A, Bardier A, Selves J, Desrousseaux M, Le Pessot F, Bonhomme B, Laverrière MH, Julié C, Eyremandi RP, Stanislas S, Bazille C, Daubech A, Lazure T, Bordier MS, Demoures A, Rullier A.

Virchows Arch. 2019 May;474(5):561-568. doi: 10.1007/s00428-019-02534-8. Epub 2019 Feb 6.

PMID:
30729335
9.

Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis.

Solass W, Sempoux C, Carr NJ, Bibeau F, Neureiter D, Jäger T, Di Caterino T, Brunel C, Klieser E, Fristrup CW, Mortensen MB, Detlefsen S.

Histopathology. 2019 Jun;74(7):1014-1024. doi: 10.1111/his.13829. Epub 2019 Apr 14.

PMID:
30687944
10.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A.

JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942.

PMID:
30452494
11.

Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival.

Quénet F, Pissas MH, Gil H, Roca L, Carrère S, Sgarbura O, Rouanet P, de Forges H, Khellaf L, Deshayes E, Ychou M, Bibeau F.

Surgery. 2019 Apr;165(4):703-711. doi: 10.1016/j.surg.2018.10.006. Epub 2018 Nov 16.

PMID:
30449697
12.

The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis.

Péron J, Mercier F, Tuech JJ, Younan R, Sideris L, Gelli M, Dumont F, Le Roy B, Sgarbura O, Lo Dico R, Bibeau F, Glehen O, Passot G; on behalf BIG-RENAPE working groups.

Surgery. 2019 Feb;165(2):476-484. doi: 10.1016/j.surg.2018.07.027. Epub 2018 Sep 7.

PMID:
30197280
13.

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.

Lab Invest. 2018 Mar;98(3):371-379. doi: 10.1038/labinvest.2017.124. Epub 2017 Dec 18.

14.

[The MSI status: An almost ideal marker!]

Bibeau F.

Ann Pathol. 2017 Dec;37(6):439-440. doi: 10.1016/j.annpat.2017.11.002. French. No abstract available.

PMID:
29224689
15.

[FREGAT: French clinico-biological database dedicated to esogastric cancers].

Renaud F, Bibeau F, Leteurtre E, Delaeter C, Dib M, Harter V, Adenis A, Piessen G, Mariette C; FREGAT working group.

Ann Pathol. 2017 Dec;37(6):457-466. doi: 10.1016/j.annpat.2017.10.005. Epub 2017 Nov 28. French.

PMID:
29196094
16.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T.

Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.

PMID:
29055842
17.

The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei.

Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK.

Histopathology. 2017 Dec;71(6):847-858. doi: 10.1111/his.13324. Epub 2017 Sep 19. Review.

PMID:
28746986
18.

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M.

J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046-017-0558-5.

19.

Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

Valmary-Degano S, Colpart P, Villeneuve L, Monnien F, M'Hamdi L, Lang Averous G, Capovilla M, Bibeau F, Laverriere MH, Verriele-Beurrier V, Ben Rejeb H, Dartigues P, Hommell-Fontaine J, Gilly FN, Isaac S, Mery E; French RENAPE Network.

Eur J Surg Oncol. 2017 Oct;43(10):1915-1923. doi: 10.1016/j.ejso.2017.05.009. Epub 2017 May 18.

PMID:
28619621
20.

Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.

Prieur A, Cappellini M, Habif G, Lefranc MP, Mazard T, Morency E, Pascussi JM, Flacelière M, Cahuzac N, Vire B, Dubuc B, Durochat A, Liaud P, Ollier J, Pfeiffer C, Poupeau S, Saywell V, Planque C, Assenat E, Bibeau F, Bourgaux JF, Pujol P, Sézeur A, Ychou M, Joubert D.

Clin Cancer Res. 2017 Sep 1;23(17):5267-5280. doi: 10.1158/1078-0432.CCR-17-0533. Epub 2017 Jun 9.

21.

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P.

Eur J Cancer. 2017 May;76:68-75. doi: 10.1016/j.ejca.2017.02.003. Epub 2017 Mar 8.

PMID:
28284171
22.

The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, Gilly FN; RENAPE Network.

Orphanet J Rare Dis. 2017 Feb 17;12(1):37. doi: 10.1186/s13023-017-0571-y.

23.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L; Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED0), Société Française de Radiothérapie Oncologique (SFRO).

Dig Liver Dis. 2017 Apr;49(4):359-367. doi: 10.1016/j.dld.2017.01.152. Epub 2017 Jan 20.

PMID:
28179091
24.

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].

Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F.

Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26. Review. French.

PMID:
28131419
25.

[Immune response and digestive cancers: Prognostic and therapeutic implications].

Bibeau F, Bazille C, Svrcek M, Pierson R, Lagorce-Pagès C, Cohen R, André T.

Ann Pathol. 2017 Feb;37(1):111-116. doi: 10.1016/j.annpat.2016.12.008. Epub 2017 Jan 19. Review. French.

PMID:
28111038
26.

[A special issue dedicated to immuno-oncology].

Bibeau F, Badoual C.

Ann Pathol. 2017 Feb;37(1):1-2. doi: 10.1016/j.annpat.2016.11.004. Epub 2017 Jan 18. French. No abstract available.

PMID:
28109693
27.

Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function.

Guiu B, Quenet F, Escal L, Bibeau F, Piron L, Rouanet P, Fabre JM, Jacquet E, Denys A, Kotzki PO, Verzilli D, Deshayes E.

Eur Radiol. 2017 Aug;27(8):3343-3352. doi: 10.1007/s00330-017-4744-9. Epub 2017 Jan 18.

PMID:
28101681
28.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

29.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V.

Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1.

30.

Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS).

Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F.

Pleura Peritoneum. 2016 Jun 1;1(2):99-107. doi: 10.1515/pp-2016-0011. Epub 2016 Jun 7.

31.

Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

Boissière-Michot F, Frugier H, Ho-Pun-Cheung A, Lopez-Crapez E, Duffour J, Bibeau F.

Virchows Arch. 2016 Aug;469(2):135-44. doi: 10.1007/s00428-016-1958-1. Epub 2016 May 25.

PMID:
27220764
32.

Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B.

Radiology. 2016 Aug;280(2):446-54. doi: 10.1148/radiol.2016150702. Epub 2016 Feb 26.

33.

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR.

Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.

34.

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ.

BMC Cancer. 2015 Dec 18;15:986. doi: 10.1186/s12885-015-1977-3.

35.

Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options.

Duffour J, Combes A, Crapez E, Boissière-Michot F, Bibeau F, Senesse P, Ychou M, Courraud J, de Forges H, Roca L.

J Genet Couns. 2016 Jun;25(3):432-42. doi: 10.1007/s10897-015-9888-7. Epub 2015 Sep 22.

PMID:
26392361
36.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group.

Ann Oncol. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.

37.

Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Colombo PE, du Manoir S, Orsett B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C.

Oncotarget. 2015 Sep 29;6(29):28327-40. doi: 10.18632/oncotarget.5069.

38.

Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey.

Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, Pocard M, Gladieff L, Bereder JM, Brigand C, Classe JM, Guilloit JM, Quenet F, Abboud K, Arvieux C, Bibeau F, De Chaisemartin C, Delroeux D, Durand-Fontanier S, Goasguen N, Gouthi L, Heyd B, Kianmanesh R, Leblanc E, Loi V, Lorimier G, Marchal F, Mariani P, Mariette C, Meeus P, Msika S, Ortega-Deballon P, Paineau J, Pezet D, Piessen G, Pirro N, Pomel C, Porcheron J, Pourcher G, Rat P, Regimbeau JM, Sabbagh C, Thibaudeau E, Torrent JJ, Tougeron D, Tuech JJ, Zinzindohoue F, Lundberg P, Herin F, Villeneuve L; BIG-RENAPE Working Group.

Eur J Surg Oncol. 2015 Oct;41(10):1361-7. doi: 10.1016/j.ejso.2015.07.012. Epub 2015 Jul 29.

PMID:
26263848
39.

[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].

Bibeau F.

Ann Pathol. 2015 Aug;35(4):347-50. doi: 10.1016/j.annpat.2015.06.005. Epub 2015 Jul 15. Review. French. No abstract available.

PMID:
26188675
40.

[Peritoneal tumor pathology - case no. 8: desmoplastic small round cell tumor].

Bibeau F.

Ann Pathol. 2015 Aug;35(4):357-61. doi: 10.1016/j.annpat.2015.06.004. Epub 2015 Jul 16. Review. French. No abstract available.

PMID:
26188674
41.

Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.

Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, Roques S, Montels F, Laberenne AC.

J Mol Diagn. 2015 Jul;17(4):366-73. doi: 10.1016/j.jmoldx.2015.02.004. Epub 2015 May 5.

PMID:
25952101
42.

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A.

Oncotarget. 2015 May 20;6(14):12796-808.

43.

The Lauren classification highlights the role of epithelial-to-mesenchymal transition in gastric carcinogenesis: an immunohistochemistry study of the STAT3 and adhesion molecules expression.

Susman S, Barnoud R, Bibeau F, Borini F, Pocard M, Tomuleasa C, Sabourin JC.

J Gastrointestin Liver Dis. 2015 Mar;24(1):77-83. doi: 10.15403/jgld.2014.1121.sus.

44.

The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.

Kersual N, Garambois V, Chardès T, Pouget JP, Salhi I, Bascoul-Mollevi C, Bibeau F, Busson M, Vié H, Clémenceau B, Behrens CK, Estupina P, Pèlegrin A, Navarro-Teulon I.

MAbs. 2014;6(5):1314-26. doi: 10.4161/mabs.29316.

45.

[Precision medicine, decision medicine].

Bibeau F, Sabourin JC.

Ann Pathol. 2014 Oct;34(5):347-8. doi: 10.1016/j.annpat.2014.09.002. Epub 2014 Oct 18. French. No abstract available.

PMID:
25439986
46.

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer.

Boissière-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le Pessot F, Sabourin JC, Bibeau F.

Oncoimmunology. 2014 Jun 25;3:e29256. eCollection 2014.

47.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P.

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

48.

Utility of reassessment after neoadjuvant therapy and difficulties in interpretation.

Pierredon-Foulongne MA, Nougaret S, Bibeau F, Rouanet P, Delhom E, Lonjon J, Ragu N, Colleau J, Schembri V, Guiu B, Gallix B.

Diagn Interv Imaging. 2014 May;95(5):495-503. doi: 10.1016/j.diii.2014.03.010. Epub 2014 Apr 22. Review.

49.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M.

Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.

PMID:
24658074
50.

[Peritoneal malignant mesothelioma: review and recent data].

Mery É, Hommell-Fontaine J, Capovilla M, Chevallier A, Bibeau F, Croce S, Dartigues P, Kaci R, Lang-Averous G, Laverriere MH, Leroux-Broussier A, Poizat F, Robin N, Valmary-Degano S, Verriele-Beurrier V, Villeneuve L, Isaac S.

Ann Pathol. 2014 Feb;34(1):26-33. doi: 10.1016/j.annpat.2014.01.004. Epub 2014 Feb 11. Review. French.

PMID:
24630634

Supplemental Content

Loading ...
Support Center